Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Melanoma and Skin Cancer Trials Limited
With
Trans Tasman Radiation Oncology Group
University of Oxford
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1-3 intracranial metastases on MRI from melanoma, locally treated with either surgical excision and/or stereotactic irradiation.
Life expectancy of at least 6 months
Aged 18 years or older
WBRT must begin within 8 weeks of completion of localised treatment and within 4 weeks of randomisation
Able to have an MRI brain scan with contrast. Estimated Glomerular Filtrate Rate (eGFR) is adequate at the discretion of the radiologist and capable of having gadolinium-containing contrast medium for MRI as per practice guidelines
Complete localised treatment of all these metastases no more than 6 weeks prior to randomisation
An Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less at randomisation
CT scan of chest, abdomen and pelvis as a minimum prior to randomisation. Scans must be within 12 weeks of randomisation
Serum Lactate Dehydrogenase (LDH) must be = or \< 2 x upper limit of normal
Able to provide written informed consent
You may not be if
Any untreated intracranial disease
Any previous intracranial treatment (surgical excision and/or stereotactic irradiation treatment and/or WBRT) prior to this diagnosis of intracranial melanoma
Evidence of leptomeningeal disease on pre-local treatment MRI scan
Patients with prior cancers, except:
* Those diagnosed more than five years ago with no evidence of disease recurrence within this time;
* Successfully treated basal cell and squamous cell skin carcinoma;
* Carcinoma in-situ of the cervix
A medical or psychiatric condition that compromises ability to give informed consent or complete the protocol
Positive urine pregnancy test for women of childbearing potential within a week of registration onto the trial
Clareo Health | Whole Brain Radiotherapy Following Local Treatment of Intracranial Metastases of Melanoma
